Bain Capital Life Sciences Investors, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Bain Capital Life Sciences Investors, LLC reported 23 stock positions worth $675.0 million. Its top holding was Newamsterdam Pharma (NAMS) at 32.5% of the portfolio, followed by Nuvalent Class A (NUVL, 15.2%) and Pharvaris (PHVS, 7.7%). Compared with Q4 2024, it sold out of 2, added to 2 and reduced 2. The biggest buy was Solid Biosciences (SLDB, shares +96%) and the biggest sale Olema Pharmaceuticals (OLMA, shares −8%).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001703031
- Portfolio Value
- $675.0M (Q1 2025)
- SEC Filing
- 0000950123-25-005465 ↗ filed May 15, 2025
Holdings Value
Holdings 23 stocks · $675.0M
| NAMS Newamsterdam Pharma Co. NV | 32.51% | 10,719,110 | $219.4M | No change |
| NUVL Nuvalent Inc. Class A | 15.21% | 1,447,267 | $102.6M | No change |
| PHVS Pharvaris NV | 7.68% | 3,303,381 | $51.9M | No change |
| IRON Disc Medicine Inc. | 7.23% | 983,500 | $48.8M | No change |
| DNTH Dianthus Therapeutics Inc. | 7.23% | 2,689,707 | $48.8M | No change |
| SVRA Savara Inc. | 7.22% | 17,600,621 | $48.8M | Add +20.8% |
| SLDB Solid Biosciences Inc. | 4.34% | 7,911,669 | $29.3M | Add +96.1% |
| OLMA Olema Pharmaceuticals Inc. | 3.81% | 6,843,954 | $25.7M | Reduce -8.4% |
| RPID Rapid Micro Biosystems Inc. Class A | 3.30% | 8,434,560 | $22.3M | No change |
| CDTX Cidara Therapeutics Inc. | 2.24% | 703,080 | $15.1M | No change |
| UPB Upstream Bio Inc. | 2.08% | 2,295,322 | $14.0M | No change |
| ANNX Annexon Inc. | 1.50% | 5,249,069 | $10.1M | No change |
| AVIR Atea Pharmaceuticals Inc. | 1.10% | 2,485,638 | $7.4M | No change |
| KYTX Kyverna Therapeutics Inc. | 0.96% | 3,368,370 | $6.5M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.59% | 16,915,784 | $4.0M | No change |
| CABA Cabaletta Bio Inc. | 0.57% | 2,760,888 | $3.8M | No change |
| TNGX Tango Therapeutics Inc. | 0.55% | 2,712,008 | $3.7M | No change |
| XLO Xilio Therapeutics Inc. | 0.49% | 4,566,817 | $3.3M | No change |
| MERSANA THERAPEUTICS INC | 0.44% | 8,663,673 | $3.0M | No change |
| IPSC Century Therapeutics Inc. | 0.38% | 5,410,361 | $2.6M | No change |
| CCCC C4 Therapeutics Inc. | 0.26% | 1,111,910 | $1.8M | No change |
| IVVD Invivyd Inc. | 0.16% | 1,799,595 | $1.1M | No change |
| NAUT Nautilus Biotechnology Inc. | 0.14% | 1,072,421 | $923K | Reduce -39.0% |
Other holdings (1): bonds, preferreds, convertibles and warrants · $899K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 100,000 | $899K | No change |
Total filed on the 13F, all lines: $675.9M.
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $1.7B | KLRA, HTFL, NAMS, SVRA, ALKS |
| Q1 2026 | 19 | $1.1B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q4 2025 | 18 | $1.3B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q3 2025 | 20 | $1.5B | HTFL, NAMS, CDTX, PHVS, OLMA |
| Q2 2025 | 22 | $798.5M | NAMS, CDTX, NUVL, PHVS, DNTH |
| Q1 2025 | 23 | $675.0M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q4 2024 | 25 | $848.7M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q3 2024 | 23 | $960.5M | NUVL, NAMS, IRON, DNTH, SVRA |
| Q2 2024 | 24 | $910.0M | NUVL, NAMS, IRON, DNTH, PHVS |
| Q1 2024 | 25 | $1.2B | NAMS, NUVL, DNTH, IRON, KYTX |